This HTML5 document contains 82 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/AHFS/
n15http://linked.opendata.cz/resource/mesh/concept/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01146/identifier/chemspider/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01146/identifier/chebi/
n19http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB01146/identifier/pharmgkb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01146/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01146/identifier/bindingdb/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01146/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01146/identifier/pubchem-substance/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01146/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01146/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01146
rdf:type
n3:Drug
n3:description
Diphenylpyraline is an antihistamine. Antihistamines used in the treatment of allergy act by competing with histamine for H 1-receptor sites on effector cells. Antihistamines prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus.
n3:generalReferences
# Lapa GB, Mathews TA, Harp J, Budygin EA, Jones SR: Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties. Eur J Pharmacol. 2005 Jan 4;506(3):237-40. Epub 2004 Dec 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15627433 # Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I: Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. J Neurol Sci. 2001 Jan 1;182(2):95-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11137513 # Puhakka H, Rantanen T, Virolainen E: Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis. J Int Med Res. 1977;5(1):37-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14039
n3:group
approved
n3:indication
For use in the treatment of allergic rhinitis, hay fever, and allergic skin disorders.
owl:sameAs
n6:DB01146 n19:DB01146
dcterms:title
Diphenylpyraline
adms:identifier
n8:D01172 n9:2992 n10:DB01146 n11:50241333 n12:59788 n16:3103 n17:46504936 n22:PA164746377 n23:Diphenylpyraline
n3:mechanismOfAction
Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms.
n3:synonym
4-(Benzhydryloxy)-1-methylpiperidine Diphenylpyralamine Difenilpiralina Diphenylpyralinum 1-Methyl-4-piperidyl benzhydryl ether 4-(Benzhydryloxy)-N-methylpiperidine 1-Methyl-4-hydroxypiperidine benzhydryl ether
n20:hasAHFSCode
n21:92-04-00%2A
n3:mixture
n13:271B48E6-363D-11E5-9242-09173F13E4C5 n13:271B48E7-363D-11E5-9242-09173F13E4C5 n13:271B48E4-363D-11E5-9242-09173F13E4C5 n13:271B48E5-363D-11E5-9242-09173F13E4C5 n13:271B48E3-363D-11E5-9242-09173F13E4C5 n13:271B48E1-363D-11E5-9242-09173F13E4C5 n13:271B48E2-363D-11E5-9242-09173F13E4C5 n13:271B48DF-363D-11E5-9242-09173F13E4C5 n13:271B48E0-363D-11E5-9242-09173F13E4C5 n13:271B48EE-363D-11E5-9242-09173F13E4C5 n13:271B48EF-363D-11E5-9242-09173F13E4C5 n13:271B48EC-363D-11E5-9242-09173F13E4C5 n13:271B48ED-363D-11E5-9242-09173F13E4C5 n13:271B48EA-363D-11E5-9242-09173F13E4C5 n13:271B48EB-363D-11E5-9242-09173F13E4C5 n13:271B48E8-363D-11E5-9242-09173F13E4C5 n13:271B48E9-363D-11E5-9242-09173F13E4C5 n13:271B48F2-363D-11E5-9242-09173F13E4C5 n13:271B48F0-363D-11E5-9242-09173F13E4C5 n13:271B48F1-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
> 99% in human serum albumin
n3:salt
n3:synthesisReference
Knox, L.H. and Kapp, R.; U.S. Patent 2,479,843; August 23, 1949; assigned to Nopco Chemical Company.
n14:hasConcept
n15:M0054943
n3:IUPAC-Name
n4:271B48F7-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B48FD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B48FC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B48F9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B48FA-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B48FB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B48F5-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B48F6-363D-11E5-9242-09173F13E4C5 n4:271B490D-363D-11E5-9242-09173F13E4C5 n4:271B48F3-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B48F4-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n24:R06AA07
n3:H-Bond-Acceptor-Count
n4:271B4903-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4904-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B48FE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B48FF-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4901-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4900-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4902-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed after oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
147-20-6
n3:category
n3:Bioavailability
n4:271B4908-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B490A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B490B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B490C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4907-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4906-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4909-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B48F8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4905-363D-11E5-9242-09173F13E4C5